Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01212081 · ClinicalTrials.gov registry record

Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
17
Enrollment target

NCT01212081 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 17 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01212081 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
17 participants
Enrollment target

Study Summary

Background: \- Individuals with schizophrenia or schizoaffective disorders have a high prevalence of cannabis use. Understanding some of the environmental factors that maintain cannabis use, such as socially triggered cravings, is a critical step in improving treatment for cannabis dependence. In recent years, virtual reality has been studied to determine whether it can be used to induce craving by using life-like cue settings. Researchers are interested in using virtual reality systems to study cannabis cravings in individuals with schizophrenia. Objectives: \- To determine if virtual reality cues will elicit cannabis craving in persons with schizophrenia who have a history of cannabis use. Eligibility: \- Individuals between 18 and 50 years of age who have been diagnosed with schizophrenia or schizoaffective disorders, are on a stable antipsychotic medication, and who have a lifetime history of at least 50 cannabis uses and average cannabis use of once per month. Design: * This study involves an initial screening visit, a study visit, and a followup visit. * Participants will be screened with a medical history and physical examination, and will complete questionnaires about their history of marijuana and other drug use. Participants will also learn how to use the virtual reality equipment at this visit. * During the study visit, participants will respond to marijuana cues using the virtual reality system while researchers monitor their heart rate, blood pressure, and sweat levels. * At the followup visit, participants will complete questionnaires about their mood and any cravings for marijuana.

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2010-09-26
Est. Completion 2012-11-26

What the Registry Record Tells You About NCT01212081

The ClinicalTrials.gov registry entry for NCT01212081 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01212081 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01212081 about?

NCT01212081 is a clinical study titled "Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality". Background: \- Individuals with schizophrenia or schizoaffective disorders have a high prevalence of cannabis use. Understanding some of the environmental factors that maintain cannabis use, such as socially triggered cravings, is a critical step in improving treatment for cannabis dependence. In r...

What is the current status of trial NCT01212081?

This trial is currently completed. The enrollment target is 17 participants. The study started on 2010-09-26. Estimated completion is 2012-11-26.

Who is sponsoring clinical trial NCT01212081?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.